Medicure has agreed to pay MGI Pharma $19 million for the U.S. marketing rights to Aggrastat injection for coronary syndrome. The drug garnered $10.9 million in U.S. sales last year. Aggrastat was launched in 1998 and is available in 82 countries.
- see the press release for more